STOCK TITAN

[Form 4] STERIS plc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Director and CEO Daniel A. Carestio reported a small open-market sale of 159 ordinary shares on 10/06/2025 at a price of $241.82 per share, leaving beneficial ownership of 51,096 shares. The filing indicates 33,054 of those shares are restricted with scheduled lapses: 06/01/2026 (4,308), 06/02/2026 (2,369), 06/03/2026 (5,937), 06/04/2026 (4,283), 06/03/2027 (5,937), 06/04/2027 (4,283), and 06/05/2028 (5,937). The form is filed individually and indicates the transaction was reported under a Rule 10b5-1 plan.

Direttore e CEO Daniel A. Carestio ha riportato una piccola vendita sul mercato aperto di 159 azioni ordinarie il 10/06/2025 a un prezzo di $241.82 per azione, lasciando una partecipazione beneficiaria di 51,096 azioni. L’ufficio di deposito indica che 33,054 di queste azioni sono soggette a restrizioni con scadenze programmate: 06/01/2026 (4,308), 06/02/2026 (2,369), 06/03/2026 (5,937), 06/04/2026 (4,283), 06/03/2027 (5,937), 06/04/2027 (4,283), e 06/05/2028 (5,937). Il modulo è presentato individualmente e indica che la transazione è stata segnalata nell’ambito di un piano Rule 10b5-1.

Director y CEO Daniel A. Carestio reportó una pequeña venta en el mercado abierto de 159 acciones ordinarias el 10/06/2025 a un precio de $241.82 por acción, dejando una titularidad beneficiaria de 51,096 acciones. El registro indica que 33,054 de esas acciones están restringidas con vencimientos programados: 06/01/2026 (4,308), 06/02/2026 (2,369), 06/03/2026 (5,937), 06/04/2026 (4,283), 06/03/2027 (5,937), 06/04/2027 (4,283), y 06/05/2028 (5,937). El formulario se presenta individualmente y indica que la transacción fue reportada bajo un plan Rule 10b5-1.

임원 겸 CEO 다니엘 A. 카레스티오159 일반주10/06/2025에 공개시장으로 소액 매도하였고, 주당 가격은 $241.82이며, 수혜 소유 지분은 51,096주로 남아 있습니다. 제출서는 33,054주가 제한되며 만료일이 예정되어 있는 항목을 표시합니다: 2026-06-01 (4,308), 2026-06-02 (2,369), 2026-06-03 (5,937), 2026-06-04 (4,283), 2027-06-03 (5,937), 2027-06-04 (4,283), 2028-06-05 (5,937). 이 서류는 개별적으로 제출되며 거래가 Rule 10b5-1 계획 아래 보고되었다고 명시합니다.

Directeur et PDG Daniel A. Carestio a signalé une petite vente sur le marché libre de 159 actions ordinaires le 10/06/2025 à un prix de $241.82 par action, laissant une propriété bénéficiaire de 51,096 actions. Le dépôt indique que 33,054 de ces actions sont restreintes avec des échéances prévues: 06/01/2026 (4,308), 06/02/2026 (2,369), 06/03/2026 (5,937), 06/04/2026 (4,283), 06/03/2027 (5,937), 06/04/2027 (4,283), et 06/05/2028 (5,937). Le formulaire est déposé individuellement et indique que la transaction a été signalée dans le cadre d’un plan Rule 10b5-1.

Geschäftsführer und CEO Daniel A. Carestio meldete einen kleinen Verkauf am freien Markt von 159 Stammaktien am 10/06/2025 zu einem Preis von $241.82 pro Aktie und belässt eine wirtschaftliche Eigentümerschaft von 51.096 Aktien. Die Einreichung gibt an, dass 33.054 dieser Aktien eingeschränkt sind mit geplanten Verfallterminen: 06/01/2026 (4.308), 06/02/2026 (2.369), 06/03/2026 (5.937), 06/04/2026 (4.283), 06/03/2027 (5.937), 06/04/2027 (4.283), und 06/05/2028 (5.937). Das Formular wird einzeln eingereicht und gibt an, dass die Transaktion unter einem Rule 10b5-1-Plan gemeldet wurde.

المدير التنفيذي والرئيس التنفيذي دانيال أ. كارستيـو أبلغ عن بيع بسيط في السوق المفتوحة لـ 159 سهماً عاديّاً في 10/06/2025 بسعر $241.82 للسهم، تاركاً ملكية مستفيدة قدرها 51,096 سهماً. يُشير الملف إلى أن 33,054 من هذه الأسهم مقيدة مع انتهاء محدد: 06/01/2026 (4,30806/02/2026 (2,36906/03/2026 (5,93706/04/2026 (4,28306/03/2027 (5,93706/04/2027 (4,283)، و 06/05/2028 (5,937). يُقدَّم النموذج بشكل فردي ويُشير إلى أن الصفقة أُبلغ عنها ضمن خطة Rule 10b5-1.

董事总经理兼首席执行官Daniel A. Carestio报告在公开市场进行了一笔小额出售,共出售了 159 只普通股,价格为每股 $241.82,日期为 10/06/2025,经济利益持有为 51,096 股。备案显示其中 33,054 只股票受限,分阶段到期:06/01/2026 (4,308),06/02/2026 (2,369),06/03/2026 (5,937),06/04/2026 (4,283),06/03/2027 (5,937),06/04/2027 (4,283),以及 06/05/2028 (5,937)。该表格为单独提交,且交易据称是在 Rule 10b5-1 计划下报告的。

Positive
  • Transaction reported under a Rule 10b5-1 plan, indicating a pre-established trading arrangement
  • Form filed promptly and includes a clear vesting schedule for restricted shares
Negative
  • Insider sold 159 shares, reducing direct holdings (immaterial in size)
  • 33,054 shares are restricted, which will vest in tranches through 06/05/2028, potentially increasing float over time

Insights

Small, routine sale by an insider under a 10b5-1 plan; majority of holdings remain restricted.

The reported sale of 159 shares at $241.82 is de minimis relative to total holdings of 51,096 shares, and the filing marks the transaction as pursuant to a Rule 10b5-1 plan, which provides a pre-established trading schedule.

The holding profile shows 33,054 restricted shares with specific vesting dates through 06/05/2028, indicating staged equity retention that ties a material portion of insider equity to future time-based milestones.

Transaction size is immaterial but disclosure and vesting schedule are investor-relevant.

The disposal code and reported price confirm an open-market sale on 10/06/2025; because only 159 shares were sold, there is no immediate material change to ownership percentage.

Investors monitoring insider alignment should note the detailed vesting timetable with multiple tranches maturing between 06/01/2026 and 06/05/2028, which could incrementally increase freely tradable shares over that horizon.

Direttore e CEO Daniel A. Carestio ha riportato una piccola vendita sul mercato aperto di 159 azioni ordinarie il 10/06/2025 a un prezzo di $241.82 per azione, lasciando una partecipazione beneficiaria di 51,096 azioni. L’ufficio di deposito indica che 33,054 di queste azioni sono soggette a restrizioni con scadenze programmate: 06/01/2026 (4,308), 06/02/2026 (2,369), 06/03/2026 (5,937), 06/04/2026 (4,283), 06/03/2027 (5,937), 06/04/2027 (4,283), e 06/05/2028 (5,937). Il modulo è presentato individualmente e indica che la transazione è stata segnalata nell’ambito di un piano Rule 10b5-1.

Director y CEO Daniel A. Carestio reportó una pequeña venta en el mercado abierto de 159 acciones ordinarias el 10/06/2025 a un precio de $241.82 por acción, dejando una titularidad beneficiaria de 51,096 acciones. El registro indica que 33,054 de esas acciones están restringidas con vencimientos programados: 06/01/2026 (4,308), 06/02/2026 (2,369), 06/03/2026 (5,937), 06/04/2026 (4,283), 06/03/2027 (5,937), 06/04/2027 (4,283), y 06/05/2028 (5,937). El formulario se presenta individualmente y indica que la transacción fue reportada bajo un plan Rule 10b5-1.

임원 겸 CEO 다니엘 A. 카레스티오159 일반주10/06/2025에 공개시장으로 소액 매도하였고, 주당 가격은 $241.82이며, 수혜 소유 지분은 51,096주로 남아 있습니다. 제출서는 33,054주가 제한되며 만료일이 예정되어 있는 항목을 표시합니다: 2026-06-01 (4,308), 2026-06-02 (2,369), 2026-06-03 (5,937), 2026-06-04 (4,283), 2027-06-03 (5,937), 2027-06-04 (4,283), 2028-06-05 (5,937). 이 서류는 개별적으로 제출되며 거래가 Rule 10b5-1 계획 아래 보고되었다고 명시합니다.

Directeur et PDG Daniel A. Carestio a signalé une petite vente sur le marché libre de 159 actions ordinaires le 10/06/2025 à un prix de $241.82 par action, laissant une propriété bénéficiaire de 51,096 actions. Le dépôt indique que 33,054 de ces actions sont restreintes avec des échéances prévues: 06/01/2026 (4,308), 06/02/2026 (2,369), 06/03/2026 (5,937), 06/04/2026 (4,283), 06/03/2027 (5,937), 06/04/2027 (4,283), et 06/05/2028 (5,937). Le formulaire est déposé individuellement et indique que la transaction a été signalée dans le cadre d’un plan Rule 10b5-1.

Geschäftsführer und CEO Daniel A. Carestio meldete einen kleinen Verkauf am freien Markt von 159 Stammaktien am 10/06/2025 zu einem Preis von $241.82 pro Aktie und belässt eine wirtschaftliche Eigentümerschaft von 51.096 Aktien. Die Einreichung gibt an, dass 33.054 dieser Aktien eingeschränkt sind mit geplanten Verfallterminen: 06/01/2026 (4.308), 06/02/2026 (2.369), 06/03/2026 (5.937), 06/04/2026 (4.283), 06/03/2027 (5.937), 06/04/2027 (4.283), und 06/05/2028 (5.937). Das Formular wird einzeln eingereicht und gibt an, dass die Transaktion unter einem Rule 10b5-1-Plan gemeldet wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Carestio Daniel A

(Last) (First) (Middle)
70 SIR JOHN ROGERSON'S QUAY

(Street)
DUBLIN 2 L2 D02 R296

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
STERIS plc [ STE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 10/06/2025 S 159 D $241.82 51,096(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. As of October 6, 2025, 33,054 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 4,308 on June 1, 2026; 5,937 on June 3, 2026; 2,369 on June 2, 2026; 4,283 on June 4, 2026; 5,937 on June 3, 2027; 4,283 on June 4, 2027; and 5,937 on June 5, 2028.
Remarks:
/s/ John P. Ubbing, Authorized Representative under Power of Attorney 10/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the STERIS (STE) Form 4 filed by Daniel A. Carestio disclose?

It disclosed an open-market sale of 159 ordinary shares on 10/06/2025 at $241.82, leaving beneficial ownership of 51,096 shares.

Was the sale by the STE insider executed under a 10b5-1 plan?

Yes. The filing indicates the transaction was made pursuant to a Rule 10b5-1 written plan.

How many of Daniel Carestio's STERIS shares are restricted and when do they vest?

33,054 shares are restricted with vesting tranches on 06/01/2026, 06/02/2026, 06/03/2026, 06/04/2026, 06/03/2027, 06/04/2027, and 06/05/2028.

Does the Form 4 indicate a material change in ownership for STE?

No. The sale of 159 shares is minor relative to total beneficial ownership of 51,096 shares and does not indicate a material ownership change.

Who signed the Form 4 for the reporting person?

The form is signed by John P. Ubbing, as Authorized Representative under Power of Attorney, dated 10/08/2025.
Steris Plc

NYSE:STE

STE Rankings

STE Latest News

STE Latest SEC Filings

STE Stock Data

23.79B
98.18M
0.3%
97.19%
0.82%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
DUBLIN